- Home
- GEHC vs TAK Comparison
GEHC vs TAK Comparison
Compare GEHC & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GEHC | TAK |
|---|---|---|
| Founded | 1892 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GEHC | TAK |
|---|---|---|
| Price | $79.23 | $18.08 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $91.17 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 3.6M |
| Earning Date | 02-04-2026 | 01-29-2026 |
| Dividend Yield | 0.18% | ★ 2.98% |
| EPS Growth | ★ 4.84 | N/A |
| EPS | ★ 4.55 | 0.45 |
| Revenue | $20,625,000,000.00 | ★ $28,475,252,603.00 |
| Revenue This Year | $5.90 | N/A |
| Revenue Next Year | $4.52 | $0.47 |
| P/E Ratio | ★ $17.38 | $39.45 |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $57.65 | $12.99 |
| 52 Week High | $94.80 | $17.99 |
Technical Indicators
Market Signals| Indicator | GEHC | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 77.87 |
| Support Level | $78.59 | $17.58 |
| Resistance Level | $85.54 | $17.99 |
| Average True Range (ATR) | 2.20 | 0.23 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 22.17 | 100.00 |
Price Performance
Historical ComparisonAbout GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.